Latest Breaking News On - Discovery engine - Page 13 : comparemela.com

Arvinas Inc (ARVN) Reports Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial

Arvinas Inc (ARVN) Reports Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

John houstonJeff boyleKirsten owensAaron peckArvinas incCompany phaseExchange commissionJefferies healthcare conferenceResponse evaluation criteriaSolid tumorsDiscovery engineLooking statements thisPrivate securities litigation reform actAnnual report

Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations

Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Arvinas to Participate in Upcoming Investor Conferences

05.06.2023 - NEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) - Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two .

Jeff boyleArvinas incGoldman sachsHealthcare conferenceAnnual global healthcare conferenceDiscovery engine

Immunome (IMNM) Publishes Preclinical Research Demonstrating that Inhibition of IL-38

Immunome (IMNM) Publishes Preclinical Research Demonstrating that Inhibition of IL-38
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAndrew mielachPurnanand sarmaLaurence wattsMatthew robinsonExchange commissionDrug administrationLifesci communicationsImmunome incChief technology officerDiscovery engineChief executive officerPrivate securities litigation reform actAnnual reportUnited states securities

Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity

Immunome, Inc. , a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced the. | May 23, 2023

Matthew robinsonPurnanand sarmaImmunome incChief technology officerDiscovery engineChief executive officerNc stock exchangePress releaseNnounced imnm us45257u1088